APPLICANTS: SERIAL NO.:

Canaani et ai. 09/975,300

FILED:

Page 2

October 12, 2001

## REMARKS

In the Office Action, the Examiner asserted that restriction to one invention is required under 35 U.S.C 121.

In response, Applicants elect with traverse, Group I, drawn to method of screening molecule, which has synthetic lethal property when in combination with a gene of interest and a kit. The following claims are readable on the elected group: claims 1-9 and 84-85, claim 1 being a generic claims directed to method of screening molecule, which have synthetic lethal property when in combination with a gene of interest.

In addition, election of a single species of the claimed invention for a single species of screening molecule, a single species of gene of interest, a single species of first reporter gene, a single species of second reporter gene, a single species of selectable marker, a single species of selection compound: a single species of cells, a single species of vector vehicle, a single species of drug, a single species of survival plasmid, a single mutant gene of interest, a single gene of interest which is overexpressed, is required under 35 U.S.C. §121.

In response, Applicants elect the following species:

- a) a single species of screening molecule: CHEMICAL REAGENT
- b) a single species of gene of interest: HGPRT
- c) a single species of first reporter gene: SAPPHIRE GREEN FLUORESCENT

PROTEIN (sphGFP)

d) a single species of second reporter gene: TOPAZ GREEN FLUORESCENT

PROTEIN (tpzGFP)

e) a single species of selectable marker: HYGROMYCIN B RESISTANCE GENE

(hgromycin B acetyl transferase)

- f) a single species of selection compound: HYGROMYCIN B
- g) a single species of cells: HT1080 fibrosarcoma human cells
- h) a single species of vector vehicle: pREP9
- i) a single species of drug: MIZORIBINE

APPLICANTS:

Canaani et ai. 09/975,300

SERIAL NO.: FILED:

October 12, 2001

Page 3

j) a single species of survival plasmid: EBV-BASED EPISOMAL VECTOR

k) a single mutant gene of interest: HGPRT

l) a single gene of interest which is overexpressed: there are no specific species in the above

identified application.

Claims 1-9 and 84-85 are readable on the elected species:

No fee is deemed necessary for filing this Communication. However, if any fee is required, the undersigned Attorney hereby authorizes the United States Patent and Trademark Office to charge Deposit Account 05-0649.

Mark S. Cohen

Attorney for Applicant(s) Registration No. 42425

Dated: November 3, 2003

Eitan, Pearl, Latzer & Cohen Zedek, LLP.

10 Rockefeller Plaza, Suite 1001 New York, New York 10020

Tel: (212) 632-3480 Fax: (212) 632-3490